Clinical Computing PLC
07 December 2007
CLINICAL COMPUTING PLC ('THE COMPANY')
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
7 December 2007
The Board of Clinical Computing Plc (the 'Company') announces that on 5 December
2007, it granted options over 1,800,000 new ordinary shares of 1p each to
Joseph G Marlovits, Chief Executive under the terms of the Company's Unapproved
Executive Share Option Scheme. These options are exercisable from 5 December
2010 to 4 December 2017 and have an exercise price of 3.25p (being the average
of the middle market price for the three preceding dealing days). There was no
consideration paid upon the grant of the options and there are no performance
criteria attached to the exercise of the options.
For further details, visit www.ccl.com or contact:
Joe Marlovits, Chief Executive 020 8747 8744
Clinical Computing plc
Ross Andrews 020 7492 4777
City Financial Associates Limited, Nominated Adviser
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.